CUTISS closed its Series C at CHF 56 million, including the CHF 25 million first closing announced in May 2024. The company said the proceeds would support the ongoing Phase 3 trial of its personalized skin graft denovoSkin and preparation for commercialization.
The financing also supports automated tissue manufacturing. CUTISS signed a collaboration agreement with new investor Rode Kruis Ziekenhuis, a Dutch hospital participating in denovoSkin trials, that could lead to its first international commercial production facility. That facility remained conditional on commercial approval of denovoSkin.
